An ancient, archaeal splicing endonuclease provides a promising alternative for gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Long, M.B., Jones, J.P., Sullenger, B.A. & Byun, J. J. Clin. Invest. 112, 312–318 (2003).
Garcia-Blanco, M.A. J. Clin. Invest. 112, 474–480 (2003).
Deidda, G., Rossi, N. & Tocchini-Valentini, G.P. Nat. Biotechnol. 21, 1499–1504 (2003).
Sazani, P. & Kole, R. J. Clin. Invest. 112, 481–486 (2003).
Puttaraju, M. et al. Nat. Biotechnol. 17, 246–252 (1999).
Liu, X. et al. Nat. Biotechnol. 20, 47–52 (2002).
Chao, H. et al. Nat. Med. 9, 1015–1019 (2003).
Sullenger, B. & Cech, T. Nature 317, 619–622 (1994).
Watanabe, T. & Sullenger, B. Proc. Natl. Acad. Sci. USA 97, 8490–8494 (2000).
Rogers, C.S., Vanoye, C.G., Sullenger, B.A. & George, A.L. J. Clin. Invest. 110, 1783–1789 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M.A.G.-B. is a scientific founder and consultant to Intronn (Gaithersburg, MD), a company that is commercializing spliceosome-mediated trans-splicing.
Rights and permissions
About this article
Cite this article
Garcia-Blanco, M. Mending the message. Nat Biotechnol 21, 1448–1449 (2003). https://doi.org/10.1038/nbt1203-1448
Issue Date:
DOI: https://doi.org/10.1038/nbt1203-1448
This article is cited by
-
Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia
Journal of Molecular Medicine (2007)
-
Gene Therapy Progress and Prospects: Reprograming gene expression by trans-splicing
Gene Therapy (2005)